Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

By I. Campbell, S. Russell, David Y. H. Choong, K. Montgomery, M. Ciavarella, Christine S. F. Hooi, Briony E. Cristiano, R. Pearson, W. Phillips. Cancer Research, 2004

987 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0d10a4a7abd3d08858a7135ebb84de2f2db5c1bf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Oncogenic mutations of PIK3CA in human cancers. (2004, background): “However, due to the relatively small number of samples studied and the fact that, despite years of effort, a commonly mutated breast cancer oncogene had not yet been discovered, several groups immediately initiated more comprehensive mutational analyses of PIK3CA in breast cancer (Bachman et al. 200”
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. (2005, background): “, 2004), and is mutated at significant frequencies in other tumor types (Bachman et al., 2004; Broderick et al., 2004; Campbell et al., 2004; Samuels et al., 2004).”
Cancer genomics: from discovery science to personalized medicine (2011, background): “and other tumor types, most notably in breast cancer where it is the most commonly mutated gen”
Comprehensive molecular portraits of human breast tumors (2012, positive): “A confirmatory finding here was the high mutation frequency of PIK3CA in luminal/ER 1 breast cancers 34,35 .”
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (2012, background): “PIK3CA mutations in exons 9 and 20 have been identified in 20% of ovarian ECs and CCCs but in only 2% of HGSC [72].”
Reprogramming of fatty acid metabolism in cancer (2019, background): “PIK3CA is, in fact, one of the most commonly mutated genes in carcinomas, with up to a third of all human cancers and 40% of breast cancers carrying gain-of-function mutations.(78) There have been several extensive reviews on the specific nodes that constitute PI3K signalling,(74,75,79) and their on”
PI3K signalling: the path to discovery and understanding (2012, background): “Equally influential were the reports in 2004 showing that many solid tumours have somatic activating mutations in PIK3CA”
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. (2005, background): “have published a PIK3CA mutational study including 70 primary breast tumors but found no association to histologic subtype, grade, ER or node status (22).”
PI3K/Akt: getting it right matters (2008, background): “One caveat for targeting Akt, however, is that genetic changes in upstream signaling molecules (for example, PIK3CA) will not only affect Akt signaling, but also other parallel pathways that are regulated by these upstream activators.”
Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, positive): “Another mechanism by which activation of PI3K signaling occurs is through activating mutations of PIK3CA, which has been detected in 20% of low-grade endometrioid carcinomas (42).”